The “Development of Biomaterial-based Delivery Systems for Parkinson’s disease – an Integrated Pan-European Approach” project (short: BrainMatTrain) has received 4 M€ from the EU’s Horizon 2020 grant programme, under the Marie Skłodowska-Curie European Training Networks Action.
The BrainMatTrain-project will develop new technology to target both the inflammatory and neurodegenerative phases of Parkinson’s disease, as currently, the symptoms of the disease are treated using drugs which do not address the underlying cause of the disease, or slow down progressive neuro-degeneration.
The consortium hopes to develop the first disease-modifying therapy for Parkinson’s which could slow down the progression of the disease rather than offering mere symptomatic benefits. The goal of the project is to engineer functionalised biomaterials that will induce neuroregeneration in the Parkinsonian brain. These biomaterials will supply the local microenvironment around damaged tissue with appropriate therapeutic signalling factors.
Professor Jenny Emnéus from DTU Nanotech participates in the consortium which consists of partners from France, Austria, Sweden, the Netherlands, the United Kingdom and Ireland from both universities and industry. The project is headed by Centre for Research in Medical Devices at NUI Galway, Ireland.
The project will run for 4 years from 2016-2020.